ShareValue scores for RAFA.TA: Valuation 50, Quality 59, Growth 50, Health 53.
RAFA.TATASE
Rafa Laboratories Ltd.
₪16.40
(-0.06%)
Updated
RAFA.TATASE
Rafa Laboratories Ltd.
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
vs Tel Aviv-listed Healthcare stocks
Company Details
Rafa Laboratories Ltd., a pharmaceutical company, manufactures, markets, and distributes prescription (Rx) and over-the-counter (OTC) medicines in Israel. The company offers sterile and aseptic injectable products, as well as formulations for combination devices such as auto-injectors. It also offers primary and secondary packaging solutions, including blisters, bottles, tubes, ampoules, cartridges, suppositories, and serialization services. In addition, it develops and offers auto-injector products for emergency use and protection against chemical warfare, as well as products to treat trauma, pain, and additional ABC (atomic, biological, and chemical) threats. The company was founded in 1937 and is based in Jerusalem, Israel.
Score Analysis
AI Investment Thesis
Rafa Laboratories Ltd. is fairly valued: its P/S of 3.60 is higher than 50% of Tel Aviv-listed Healthcare peers, while P/E and EV/EBITDA are not available.
Profitability is the standout, with a 26.78% margin versus a negative global sector average, and H1-2026 operating cash flow of ₪45.4M exceeded net income.
On 9 November 2026 Israel's Ministry of Health approved ImmunityBio's ANKTIVA plus BCG, with Rafa as exclusive Israeli commercializer.